Results 91 to 100 of about 6,658 (202)

Effects of rucaparib on tumor vessel perfusion may be dependent on PARP.

, 2015
Panels A and B; B16 tumours were established in PARP WT or KO female mice. The extent of vessel ‘mismatch’ following the administration of the perfusion markers Hoechst 33342 and carbocyanin was reduced by rucaparib (1 mg/kg) in tumors established in WT ...
Tracy Robson (282407), Hiu-Fung Yuen (276126), Declan O’Rourke (692863), Martin G. O’Rourke (692861), Cian M. McCrudden (276127), Chris Hagan (692868), Joe M. O’Sullivan (275899), David G. Hirst (282406), Huw D. Thomas (114714), Nicola J. Curtin (351064), Kim E. Cherry (692862), Patrick Keane (692866), Chris Shaw (285026), Kaye J. Williams (692869), Muhammad Babur (692864), Brian A. Telfer (692865), Thiagarajan Nambirajan (692867)   +16 more
core   +1 more source

Supplementary Appendix from A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

, 2017
Supplementary data include the following: Figure S1. Rucaparib plasma concentration-time profiles following once daily oral administration Figure S2.
Ana Montes (4097680), Lee-may Chen (9101985), Jen Borrow (15009473), Yvette Drew (11812133), Howard A. Burris (12071261), Amit M. Oza (14981475), Manish R. Patel (15004347), Patricia LoRusso (353749), Rebecca Kristeleit (14986077), Heidi Giordano (15009461), Tamar Safra (11536160), Lindsey Rolfe (14998169), Jeff Isaacson (15009467), Ronnie Shapira-Frommer (382252), Susan M. Domchek (8115968), Jim Xiao (15009470), Sandra Goble (15009464), Judith Balmaña (395210), Lara Maloney (2949822), Geoffrey I. Shapiro (14874999)   +19 more
core   +1 more source

PARP Activity in Peripheral Blood Lymphocytes as a Predictive Biomarker for PARP Inhibition in Tumor Tissues - A Population Pharmacokinetic/Pharmacodynamic Analysis of Rucaparib

Purpose: Rucaparib is a potent Poly (ADP-ribose) Polymerase (PARP) inhibitor currently under clinical development. The objectives of this analysis were to establish population PK and PK/PD models for rucaparib, and to evaluate the predictability of PARP ...
Plummer R, Li CZ, Kern KA, Curtin NJ, Shalinsky DR, Kirkpatrick TR, Sun W, Wang DD, Zhang SZ, Sam WJ   +9 more
core   +1 more source

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway

Journal of Pharmaceutical Policy and Practice
Background Withdrawals of drug indications may reveal potential inadequacies in the regulatory approval processes of new drugs. Understanding potential weaknesses of the regulatory approval process is paramount given the increasing use of expedited ...
Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner   +4 more
doaj   +1 more source

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers [PDF]

PARP inhibition; Rucaparib; Triple-negative breast cancerInhibición de PARP; Rucaparib; Cáncer de mama triple negativoInhibició de PARP; Rucaparib; Càncer de mama triple negatiuBackground Combining PARP inhibitors (PARPis) with immune checkpoint ...
Redondo Sanchez, Andres, Chui, Stephen, Kristeleit, Rebecca, leary, alexandra, OAKNIN, ANA, George, A., Guan, Y, Kristeleit, R, Lin, Kevin, Oaknin, A, Leary, A, Shemesh, Colby S, George, Angela, Liste-Hermoso, M, Willis, Jenna, Xiao, Jim, Molinero, L, Redondo, Andres, Seiller, Aicha, Shemesh, CS, Mileshkin, Linda, Lin, Kevin K., Kristeleit, Rebecca; id_orcid, Shemesh, Colby S., Molinero, Luciana, Ray-Coquard, I, Mileshkin, L, Liste-Hermoso, Mario, George, A, Redondo, A, Xiao, J, Lin, KK, Seiller, A, Ray-Coquard, Isabelle, Guan, Yinghui, Lin, Kevin K, Shemesh, Colby, Chui, S, Willis, J   +38 more
core   +1 more source

Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Gynecologic Oncology Reports
Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib).
Bobbie J. Rimel, Dana M. Chase, Jessica Perhanidis, Armen A. Ghazarian, Ella Xiaoyan Du, Travis Wang, Jinlin Song, Amanda K. Golembesky, Jean A. Hurteau, Linda Kalilani, Ritu Salani, Bradley J. Monk   +11 more
doaj   +1 more source

Supplementary Figures 1 and 2 from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

, 2015
Supplemental Figure 1. MALDI FTICR mass spectra selected from a pixel with maximum intensity in the MS images of liver (A) and flank tumor (B) sections showing the two first isotopes of rucaparib (peaks labelled 1 and 2, respectively).
Rajendar K. Mittapalli (14928966), James Murray (1397), Alan V. Boddy (8376006), William F. Elmquist (12177973), Mark A. Schroeder (14915030), David Calligaris (1921921), Karen E. Parrish (10168575), Sani Kizilbash (15069759), Ling Cen (79141), Brett L. Carlson (8799290), Julieann Sludden (15069762), Jann N. Sarkaria (238863), Nathalie Y.R. Agar (2147080), Nicola J. Curtin (351064)   +13 more
core   +1 more source

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis

BMC Cancer
Background Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD).
Qiyu Zhu, Junru Chen, Haoyang Liu, Jinge Zhao, Chenhao Xu, Guangxi Sun, Hao Zeng   +6 more
doaj   +1 more source

Rucaparib Phosphate [PDF]

, 2020
openaire   +1 more source

Rucaparib Regimen [PDF]

, 2020
openaire   +1 more source